TY  - JOUR
T1  - ERythromycin-induced clozapine toxic reaction
AU  - Cohen L, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC
Y1  - 1996/03/25
N1  - 10.1001/archinte.1996.00440060103013
JO  - Archives of Internal Medicine
SP  - 675
EP  - 677
VL  - 156
IS  - 6
N2  - Clozapine, used in the treatment of patients with schizophrenia resistant to other neuroleptic medication, is metabolized by the hepatic microsomal system to demethyl-clozapine and clozapine-N-oxide. Changes in clozapine serum concentrations have been documented after initiation of therapy with medications known to induce or inhibit liver microsomal enzymes. These interactions are of clinical importance when diminished efficacy or increased toxic effects of clozapine therapy occur. A 34-year-old schizophrenic man had increased clozapine serum concentrations, leukocytosis, and adverse effects as a result of concomitant erythromycin therapy given for a suspected lower respiratory tract infection. Symptoms included somnolence, difficulty in coordination and ambulation, slurred speech, disorientation, and incontinence. The symptoms resolved after treatment with clozapine and erythromycin were discontinued, and treatment with clozapine was gradually resumed.(Arch Intern Med. 1996;156:675-677)
SN  - 0003-9926
M3  - doi: 10.1001/archinte.1996.00440060103013
UR  - http://dx.doi.org/10.1001/archinte.1996.00440060103013
ER  -